Tatva Chintan Pharma Chem Limited AI Stock Analysis
Want to see IN:TATVA full AI Analyst Report?
Tatva Chintan Pharma Chem Limited (TATVA) AI Stock Analysis
Tatva Chintan Pharma Chem Limited
(NSE:TATVA)
The overall score is constrained by a very high valuation and weak technical momentum. The company's financial health is a mixed bag: a robust, low-debt balance sheet provides stability, but significant margin compression and persistent negative free cash flow raise concerns about the sustainability of its capital-intensive growth. The stock's poor short-term price performance and expensive P/E ratio are the primary detractors.
Tatva Chintan Pharma Chem Limited (TATVA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 38.45B
- Dividend Yield
- 0.12%
- Average Volume (3M)
- 5,290
- Price to Earnings (P/E)
- 60.9
- Beta (1Y)
- 0.87
- Revenue Growth
- 49.69%
- EPS Growth
- 254.75%
- Country
- India
- Employees
- 793
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals - Specialty
Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model
Company Description
Tatva Chintan Pharma Chem Limited, an Indian-based enterprise, specializes in the production and distribution of diverse specialty chemicals. Its extensive product range encompasses essential components like structure-directing agents crucial for zeo...
How the Company Makes Money
Tatva Chintan Pharma Chem Limited primarily makes money by manufacturing and selling specialty chemicals—mainly SDPTCs and QAS (including bromide-based and other quaternary ammonium salts), along with specialty chemicals and electrolyte salts—to cust...
Tatva Chintan Pharma Chem Limited Financial Statement Overview
Summary
Revenue growth of 16.5% and a strong balance sheet with a 0.15 debt-to-equity ratio are positives. However, gross margin contraction to 35.9% and deeply negative free cash flow of -₹841 million due to heavy capex weigh on the score, indicating recovery with significant cash generation risks.
Income Statement
62PositiveBalance Sheet
85Very PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.50B | 5.06B | 3.83B | 3.43B | 4.24B | 4.34B |
| Gross Profit | 2.75B | 1.82B | 619.74M | 1.60B | 1.91B | 2.32B |
| EBITDA | 1.29B | 967.07M | -875.86M | 693.88M | 680.24M | 1.09B |
| Net Income | 629.18M | 420.54M | 57.13M | 303.54M | 454.87M | 958.74M |
Balance Sheet | ||||||
| Total Assets | 11.19B | 10.04B | 8.36B | 8.19B | 7.60B | 6.58B |
| Cash, Cash Equivalents and Short-Term Investments | 152.05M | 87.91M | 117.01M | 456.68M | 412.16M | 638.19M |
| Total Debt | 1.70B | 1.20B | 363.88M | 142.71M | 1.70B | 1.20B |
| Total Liabilities | 3.04B | 2.22B | 974.25M | 816.36M | 2.44B | 1.85B |
| Stockholders Equity | 8.15B | 7.82B | 7.39B | 7.37B | 5.15B | 4.73B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -841.44M | -516.01M | -304.71M | -1.75B | -687.79M |
| Operating Cash Flow | 0 | 296.30M | 246.71M | 980.44M | 277.83M | 203.78M |
| Investing Cash Flow | 0 | -1.17B | -652.54M | -1.21B | -1.01B | -1.97B |
| Financing Cash Flow | 0 | 816.19M | 165.66M | 305.19M | 377.95M | 2.35B |
Tatva Chintan Pharma Chem Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Negative. The current price of 1636.10 is below the 20-day moving average (MA) of 1652.47, below the 50-day MA of 1727.69, and above the 200-day MA of 1421.69, indicating a neutral trend. The MACD of -24.93 indicates Negative momentum. The RSI at 45.35 is Neutral, neither overbought nor oversold. The STOCH value of 43.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:TATVA.
Tatva Chintan Pharma Chem Limited Peers Comparison
Overall Rating
IN:VINATIORGA68Neutral
IN:ROSSARI65Neutral
IN:ALKYLAMINE61Neutral
IN:JUBLINGREA61Neutral
IN:TATVA52Neutral
IN:AARTIIND47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | INR 121.70B | 29.52 | ― | 0.72% | 10.98% | -5.48% | |
| 65Neutral | INR 23.69B | 15.52 | ― | 0.12% | 19.76% | 11.74% | |
| 61Neutral | INR 80.54B | 32.52 | ― | 0.64% | 13.38% | 35.82% | |
| 61Neutral | INR 91.41B | 25.83 | ― | 0.87% | 15.41% | 21.76% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | INR 38.27B | 60.86 | ― | 0.12% | 49.69% | 254.75% | |
| 47Neutral | INR 165.88B | 28.02 | ― | 0.22% | 39.85% | 103.71% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:TATVA | Tatva Chintan Pharma Chem Limited | 1636.10 | 185.44 | 12.78% | |
| IN:AARTIIND | AARTI Industries Ltd | 457.30 | 73.41 | 19.12% | |
| IN:ALKYLAMINE | Alkyl Amines Chemicals Limited | 1574.65 | -157.23 | -9.08% | |
| IN:JUBLINGREA | Jubilant Ingrevia Ltd. | 573.90 | -140.88 | -19.71% | |
| IN:ROSSARI | Rossari Biotech Ltd | 427.75 | -187.25 | -30.45% | |
| IN:VINATIORGA | Vinati Organics Limited | 1173.95 | -410.95 | -25.93% |
Tatva Chintan Pharma Chem Limited Corporate Events
Tatva Chintan Corrects Key Ratios in Updated Investor Presentation
Tatva Chintan Pharma Chem Limited operates in the specialty chemicals and pharmaceutical intermediates sector, supplying advanced chemical formulations to domestic and international markets. Listed on both BSE and NSE under the scrip code 543321 and...
Tatva Chintan Plans Analyst Meeting With Motilal Oswal
Tatva Chintan Pharma Chem Limited has announced that it will participate in a one-to-one virtual meeting with Motilal Oswal Investment Advisors Limited on 26 October 2026, as part of its regular interactions with analysts, financial institutions and...
Tatva Chintan Schedules Earnings Call for Q2 and H1 FY27 Results
Tatva Chintan Pharma Chem Limited has scheduled an earnings conference call to discuss its financial results for the quarter and half year ended 30 September 2026. The call, hosted by ICICI Securities and featuring Managing Director Chintan Shah and...
Crisil Upgrades Tatva Chintan’s Credit Ratings on Rs.245 Crore Bank Facilities
Tatva Chintan Pharma Chem Limited has received an upgrade in its credit profile from Crisil Ratings, which raised the company’s long-term rating to Crisil A-/Stable from Crisil BBB+/Stable and its short-term rating to Crisil A2+ from Crisil A2. The r...
Tatva Chintan Schedules Virtual Investor Meeting with Ventura Securities on July 30
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-on-one meeting with Ventura Securities Limited on 30 July 2026 as part of its ongoing engagement with analysts, financial institutions, and investors. The company emphasized that only publ...
Tatva Chintan Plans Investor Meeting with Motilal Oswal AMC
Tatva Chintan Pharma Chem Limited has scheduled a virtual one-to-one meeting with Motilal Oswal Asset Management Company on July 31, 2026, aimed at engaging analysts, financial institutions and investors. The company emphasized that discussions will...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026
